{"entity":{"type":"insider","cik":"0001555851","url":"/insider/0001555851","json_url":"/insider/0001555851.json","name":"Rawcliffe Adrian","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":34,"n_filings":28,"first":"2018-03-22","last":"2026-08-13","span_basis":"filed_date"},"name_variants":[{"name":"Rawcliffe Adrian","source":"filing","n_filings":28,"first_seen":"2018-03-22","last_seen":"2026-08-13"}],"transactions":[{"id":9255636,"accession":"0001193125-26-349962","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-26-349962","line_url":"/filing/0001193125-26-349962#line-1","is_derivative":false,"issuer_cik":"0001555851","issuer_name":"Wave Life Sciences, Inc.","issuer_ticker":"WVE","issuer_name_source":null,"issuer_url":"/issuer/0001555851","owner_cik":"0001555851","owner_name":"Rawcliffe Adrian","owner_display_name":"Rawcliffe Adrian","owner_url":"/insider/0001555851","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12700.0,"shares_display":"12,700","price_per_share":5.29,"price_display":"5.29","price_state":"stated","total_value":67183.0,"total_display":"67,183.00","total_whole":"67,183","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-08-12","filed_date":"2026-08-13","scope":"insider"},{"id":4941362,"accession":"0001193125-25-314742","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193125-25-314742","line_url":"/filing/0001193125-25-314742#line-2","is_derivative":false,"issuer_cik":"0001555851","issuer_name":"Wave Life Sciences Ltd.","issuer_ticker":"WVE","issuer_name_source":null,"issuer_url":"/issuer/0001555851","owner_cik":"0001555851","owner_name":"Rawcliffe Adrian","owner_display_name":"Rawcliffe Adrian","owner_url":"/insider/0001555851","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":42000.0,"shares_display":"42,000","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":630000.0,"total_display":"630,000.00","total_whole":"630,000","shares_owned_after":12700.0,"shares_owned_after_display":"12,700","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-12-08","filed_date":"2025-12-10","scope":"insider"},{"id":4531816,"accession":"0001193125-25-283619","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-25-283619","line_url":"/filing/0001193125-25-283619#line-1","is_derivative":false,"issuer_cik":"0001555851","issuer_name":"Wave Life Sciences Ltd.","issuer_ticker":"WVE","issuer_name_source":null,"issuer_url":"/issuer/0001555851","owner_cik":"0001555851","owner_name":"Rawcliffe Adrian","owner_display_name":"Rawcliffe Adrian","owner_url":"/insider/0001555851","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":16115.0,"shares_display":"16,115","price_per_share":6.79,"price_display":"6.79","price_state":"stated","total_value":109420.85,"total_display":"109,420.85","total_whole":"109,421","shares_owned_after":12700.0,"shares_owned_after_display":"12,700","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-11-13","filed_date":"2025-11-14","scope":"insider"},{"id":4922708,"accession":"0001104659-25-004605","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-25-004605","line_url":"/filing/0001104659-25-004605#line-1","is_derivative":false,"issuer_cik":"0001555851","issuer_name":"Adaptimmune Therapeutics PLC","issuer_ticker":"ADAP","issuer_name_source":null,"issuer_url":"/issuer/0001555851","owner_cik":"0001555851","owner_name":"Rawcliffe Adrian","owner_display_name":"Rawcliffe Adrian","owner_url":"/insider/0001555851","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"American Depositary Shares representing Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":30601.0,"shares_display":"30,601","price_per_share":0.5808,"price_display":"0.58","price_state":"stated","total_value":17773.0608,"total_display":"17,773.06","total_whole":"17,773","shares_owned_after":44327.0,"shares_owned_after_display":"44,327","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-17","filed_date":"2025-01-17","scope":"insider"},{"id":4167931,"accession":"0001104659-25-003775","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-25-003775","line_url":"/filing/0001104659-25-003775#line-3","is_derivative":false,"issuer_cik":"0001555851","issuer_name":"Adaptimmune Therapeutics PLC","issuer_ticker":"ADAP","issuer_name_source":null,"issuer_url":"/issuer/0001555851","owner_cik":"0001555851","owner_name":"Rawcliffe Adrian","owner_display_name":"Rawcliffe Adrian","owner_url":"/insider/0001555851","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"American Depositary Shares representing Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":29096.0,"shares_display":"29,096","price_per_share":0.5748,"price_display":"0.57","price_state":"stated","total_value":16724.3808,"total_display":"16,724.38","total_whole":"16,724","shares_owned_after":41582.0,"shares_owned_after_display":"41,582","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-15","filed_date":"2025-01-15","scope":"insider"},{"id":4167929,"accession":"0001104659-25-003775","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-25-003775","line_url":"/filing/0001104659-25-003775","is_derivative":false,"issuer_cik":"0001555851","issuer_name":"Adaptimmune Therapeutics PLC","issuer_ticker":"ADAP","issuer_name_source":null,"issuer_url":"/issuer/0001555851","owner_cik":"0001555851","owner_name":"Rawcliffe Adrian","owner_display_name":"Rawcliffe Adrian","owner_url":"/insider/0001555851","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"American Depositary Shares representing Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":30473.0,"shares_display":"30,473","price_per_share":0.5879,"price_display":"0.59","price_state":"stated","total_value":17915.0767,"total_display":"17,915.08","total_whole":"17,915","shares_owned_after":25711.0,"shares_owned_after_display":"25,711","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-13","filed_date":"2025-01-15","scope":"insider","n_lines":2},{"id":2128739,"accession":"0001104659-24-004564","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-24-004564","line_url":"/filing/0001104659-24-004564#line-2","is_derivative":false,"issuer_cik":"0001555851","issuer_name":"Adaptimmune Therapeutics PLC","issuer_ticker":"ADAP","issuer_name_source":null,"issuer_url":"/issuer/0001555851","owner_cik":"0001555851","owner_name":"Rawcliffe Adrian","owner_display_name":"Rawcliffe Adrian","owner_url":"/insider/0001555851","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"American Depositary Shares representing Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":30080.0,"shares_display":"30,080","price_per_share":0.673,"price_display":"0.67","price_state":"stated","total_value":20243.84,"total_display":"20,243.84","total_whole":"20,244","shares_owned_after":44848.0,"shares_owned_after_display":"44,848","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-17","filed_date":"2024-01-17","scope":"insider"},{"id":2128733,"accession":"0001104659-24-004564","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-24-004564","line_url":"/filing/0001104659-24-004564#line-1","is_derivative":false,"issuer_cik":"0001555851","issuer_name":"Adaptimmune Therapeutics PLC","issuer_ticker":"ADAP","issuer_name_source":null,"issuer_url":"/issuer/0001555851","owner_cik":"0001555851","owner_name":"Rawcliffe Adrian","owner_display_name":"Rawcliffe Adrian","owner_url":"/insider/0001555851","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"American Depositary Shares representing Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9304.0,"shares_display":"9,304","price_per_share":0.79,"price_display":"0.79","price_state":"stated","total_value":7350.16,"total_display":"7,350.16","total_whole":"7,350","shares_owned_after":14104.0,"shares_owned_after_display":"14,104","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-16","filed_date":"2024-01-17","scope":"insider"},{"id":2398086,"accession":"0001104659-24-003742","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-24-003742","line_url":"/filing/0001104659-24-003742#line-2","is_derivative":false,"issuer_cik":"0001555851","issuer_name":"Adaptimmune Therapeutics PLC","issuer_ticker":"ADAP","issuer_name_source":null,"issuer_url":"/issuer/0001555851","owner_cik":"0001555851","owner_name":"Rawcliffe Adrian","owner_display_name":"Rawcliffe Adrian","owner_url":"/insider/0001555851","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"American Depositary Shares representing Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":17257.0,"shares_display":"17,257","price_per_share":0.8541,"price_display":"0.85","price_state":"stated","total_value":14739.2037,"total_display":"14,739.20","total_whole":"14,739","shares_owned_after":26388.0,"shares_owned_after_display":"26,388","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-12","filed_date":"2024-01-12","scope":"insider"},{"id":2398085,"accession":"0001104659-24-003742","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-24-003742","line_url":"/filing/0001104659-24-003742#line-1","is_derivative":false,"issuer_cik":"0001555851","issuer_name":"Adaptimmune Therapeutics PLC","issuer_ticker":"ADAP","issuer_name_source":null,"issuer_url":"/issuer/0001555851","owner_cik":"0001555851","owner_name":"Rawcliffe Adrian","owner_display_name":"Rawcliffe Adrian","owner_url":"/insider/0001555851","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"American Depositary Shares representing Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11945.0,"shares_display":"11,945","price_per_share":0.8367,"price_display":"0.84","price_state":"stated","total_value":9994.3815,"total_display":"9,994.38","total_whole":"9,994","shares_owned_after":18395.0,"shares_owned_after_display":"18,395","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-11","filed_date":"2024-01-12","scope":"insider"},{"id":7891629,"accession":"0001104659-23-097853","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-23-097853","line_url":"/filing/0001104659-23-097853#line-1","is_derivative":false,"issuer_cik":"0001555851","issuer_name":"Adaptimmune Therapeutics PLC","issuer_ticker":"ADAP","issuer_name_source":null,"issuer_url":"/issuer/0001555851","owner_cik":"0001555851","owner_name":"Rawcliffe Adrian","owner_display_name":"Rawcliffe Adrian","owner_url":"/insider/0001555851","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"American Depositary Shares representing Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2403.0,"shares_display":"2,403","price_per_share":0.78,"price_display":"0.78","price_state":"stated","total_value":1874.34,"total_display":"1,874.34","total_whole":"1,874","shares_owned_after":3449.0,"shares_owned_after_display":"3,449","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-09-01","filed_date":"2023-09-01","scope":"insider"},{"id":8319290,"accession":"0001104659-23-075407","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-23-075407","line_url":"/filing/0001104659-23-075407#line-1","is_derivative":false,"issuer_cik":"0001555851","issuer_name":"Adaptimmune Therapeutics PLC","issuer_ticker":"ADAP","issuer_name_source":null,"issuer_url":"/issuer/0001555851","owner_cik":"0001555851","owner_name":"Rawcliffe Adrian","owner_display_name":"Rawcliffe Adrian","owner_url":"/insider/0001555851","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"American Depositary Shares representing Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2333.0,"shares_display":"2,333","price_per_share":0.92,"price_display":"0.92","price_state":"stated","total_value":2146.36,"total_display":"2,146.36","total_whole":"2,146","shares_owned_after":3519.0,"shares_owned_after_display":"3,519","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-06-27","filed_date":"2023-06-27","scope":"insider"},{"id":8145532,"accession":"0001104659-23-004379","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-23-004379","line_url":"/filing/0001104659-23-004379#line-1","is_derivative":false,"issuer_cik":"0001555851","issuer_name":"Adaptimmune Therapeutics PLC","issuer_ticker":"ADAP","issuer_name_source":null,"issuer_url":"/issuer/0001555851","owner_cik":"0001555851","owner_name":"Rawcliffe Adrian","owner_display_name":"Rawcliffe Adrian","owner_url":"/insider/0001555851","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"American Depositary Shares representing Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10057.0,"shares_display":"10,057","price_per_share":1.858,"price_display":"1.86","price_state":"stated","total_value":18685.906,"total_display":"18,685.91","total_whole":"18,686","shares_owned_after":13351.0,"shares_owned_after_display":"13,351","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-01-17","filed_date":"2023-01-17","scope":"insider"},{"id":8403165,"accession":"0001104659-23-003534","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-23-003534","line_url":"/filing/0001104659-23-003534#line-2","is_derivative":false,"issuer_cik":"0001555851","issuer_name":"Adaptimmune Therapeutics PLC","issuer_ticker":"ADAP","issuer_name_source":null,"issuer_url":"/issuer/0001555851","owner_cik":"0001555851","owner_name":"Rawcliffe Adrian","owner_display_name":"Rawcliffe Adrian","owner_url":"/insider/0001555851","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"American Depositary Shares representing Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":18763.0,"shares_display":"18,763","price_per_share":1.706,"price_display":"1.71","price_state":"stated","total_value":32009.678,"total_display":"32,009.68","total_whole":"32,010","shares_owned_after":24882.0,"shares_owned_after_display":"24,882","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-01-12","filed_date":"2023-01-12","scope":"insider"},{"id":8403159,"accession":"0001104659-23-003534","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-23-003534","line_url":"/filing/0001104659-23-003534#line-1","is_derivative":false,"issuer_cik":"0001555851","issuer_name":"Adaptimmune Therapeutics PLC","issuer_ticker":"ADAP","issuer_name_source":null,"issuer_url":"/issuer/0001555851","owner_cik":"0001555851","owner_name":"Rawcliffe Adrian","owner_display_name":"Rawcliffe Adrian","owner_url":"/insider/0001555851","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"American Depositary Shares representing Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13042.0,"shares_display":"13,042","price_per_share":1.7468,"price_display":"1.75","price_state":"stated","total_value":22781.7656,"total_display":"22,781.77","total_whole":"22,782","shares_owned_after":17298.0,"shares_owned_after_display":"17,298","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-01-11","filed_date":"2023-01-12","scope":"insider"},{"id":8356939,"accession":"0001104659-23-001088","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-23-001088","line_url":"/filing/0001104659-23-001088#line-1","is_derivative":false,"issuer_cik":"0001555851","issuer_name":"Adaptimmune Therapeutics PLC","issuer_ticker":"ADAP","issuer_name_source":null,"issuer_url":"/issuer/0001555851","owner_cik":"0001555851","owner_name":"Rawcliffe Adrian","owner_display_name":"Rawcliffe Adrian","owner_url":"/insider/0001555851","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"American Depositary Shares representing Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5073.0,"shares_display":"5,073","price_per_share":1.694,"price_display":"1.69","price_state":"stated","total_value":8593.662,"total_display":"8,593.66","total_whole":"8,594","shares_owned_after":6631.0,"shares_owned_after_display":"6,631","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-01-04","filed_date":"2023-01-04","scope":"insider"},{"id":6110073,"accession":"0001104659-22-097135","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-22-097135","line_url":"/filing/0001104659-22-097135#line-1","is_derivative":false,"issuer_cik":"0001555851","issuer_name":"Adaptimmune Therapeutics PLC","issuer_ticker":"ADAP","issuer_name_source":null,"issuer_url":"/issuer/0001555851","owner_cik":"0001555851","owner_name":"Rawcliffe Adrian","owner_display_name":"Rawcliffe Adrian","owner_url":"/insider/0001555851","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"American Depositary Shares representing Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2536.0,"shares_display":"2,536","price_per_share":1.9689,"price_display":"1.97","price_state":"stated","total_value":4993.1304,"total_display":"4,993.13","total_whole":"4,993","shares_owned_after":3316.0,"shares_owned_after_display":"3,316","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-09-01","filed_date":"2022-09-01","scope":"insider"},{"id":6125007,"accession":"0001104659-22-074926","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-22-074926","line_url":"/filing/0001104659-22-074926#line-1","is_derivative":false,"issuer_cik":"0001555851","issuer_name":"Adaptimmune Therapeutics PLC","issuer_ticker":"ADAP","issuer_name_source":null,"issuer_url":"/issuer/0001555851","owner_cik":"0001555851","owner_name":"Rawcliffe Adrian","owner_display_name":"Rawcliffe Adrian","owner_url":"/insider/0001555851","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"American Depositary Shares representing Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2562.0,"shares_display":"2,562","price_per_share":1.63,"price_display":"1.63","price_state":"stated","total_value":4176.06,"total_display":"4,176.06","total_whole":"4,176","shares_owned_after":3290.0,"shares_owned_after_display":"3,290","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-06-27","filed_date":"2022-06-27","scope":"insider"},{"id":6365931,"accession":"0001104659-22-005053","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-22-005053","line_url":"/filing/0001104659-22-005053#line-1","is_derivative":false,"issuer_cik":"0001555851","issuer_name":"Adaptimmune Therapeutics PLC","issuer_ticker":"ADAP","issuer_name_source":null,"issuer_url":"/issuer/0001555851","owner_cik":"0001555851","owner_name":"Rawcliffe Adrian","owner_display_name":"Rawcliffe Adrian","owner_url":"/insider/0001555851","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"American Depositary Shares representing Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11096.0,"shares_display":"11,096","price_per_share":3.1918,"price_display":"3.19","price_state":"stated","total_value":35416.2128,"total_display":"35,416.21","total_whole":"35,416","shares_owned_after":12312.0,"shares_owned_after_display":"12,312","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-01-18","filed_date":"2022-01-18","scope":"insider"},{"id":6680068,"accession":"0001104659-22-004149","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-22-004149","line_url":"/filing/0001104659-22-004149#line-2","is_derivative":false,"issuer_cik":"0001555851","issuer_name":"Adaptimmune Therapeutics PLC","issuer_ticker":"ADAP","issuer_name_source":null,"issuer_url":"/issuer/0001555851","owner_cik":"0001555851","owner_name":"Rawcliffe Adrian","owner_display_name":"Rawcliffe Adrian","owner_url":"/insider/0001555851","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"American Depositary Shares representing Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3046.0,"shares_display":"3,046","price_per_share":3.5441,"price_display":"3.54","price_state":"stated","total_value":10795.3286,"total_display":"10,795.33","total_whole":"10,795","shares_owned_after":3356.0,"shares_owned_after_display":"3,356","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-01-12","filed_date":"2022-01-13","scope":"insider"},{"id":6680059,"accession":"0001104659-22-004149","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-22-004149","line_url":"/filing/0001104659-22-004149#line-1","is_derivative":false,"issuer_cik":"0001555851","issuer_name":"Adaptimmune Therapeutics PLC","issuer_ticker":"ADAP","issuer_name_source":null,"issuer_url":"/issuer/0001555851","owner_cik":"0001555851","owner_name":"Rawcliffe Adrian","owner_display_name":"Rawcliffe Adrian","owner_url":"/insider/0001555851","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"American Depositary Shares representing Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":14362.0,"shares_display":"14,362","price_per_share":3.5567,"price_display":"3.56","price_state":"stated","total_value":51081.3254,"total_display":"51,081.33","total_whole":"51,081","shares_owned_after":15978.0,"shares_owned_after_display":"15,978","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-01-11","filed_date":"2022-01-13","scope":"insider"},{"id":6680043,"accession":"0001104659-22-001668","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-22-001668","line_url":"/filing/0001104659-22-001668#line-1","is_derivative":false,"issuer_cik":"0001555851","issuer_name":"Adaptimmune Therapeutics PLC","issuer_ticker":"ADAP","issuer_name_source":null,"issuer_url":"/issuer/0001555851","owner_cik":"0001555851","owner_name":"Rawcliffe Adrian","owner_display_name":"Rawcliffe Adrian","owner_url":"/insider/0001555851","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"American Depositary Shares representing Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5532.0,"shares_display":"5,532","price_per_share":4.0642,"price_display":"4.06","price_state":"stated","total_value":22483.1544,"total_display":"22,483.15","total_whole":"22,483","shares_owned_after":6172.0,"shares_owned_after_display":"6,172","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-01-04","filed_date":"2022-01-05","scope":"insider"},{"id":4282481,"accession":"0001104659-21-112179","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-21-112179","line_url":"/filing/0001104659-21-112179#line-1","is_derivative":false,"issuer_cik":"0001555851","issuer_name":"Adaptimmune Therapeutics PLC","issuer_ticker":"ADAP","issuer_name_source":null,"issuer_url":"/issuer/0001555851","owner_cik":"0001555851","owner_name":"Rawcliffe Adrian","owner_display_name":"Rawcliffe Adrian","owner_url":"/insider/0001555851","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"American Depositary Shares representing Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2782.0,"shares_display":"2,782","price_per_share":5.195,"price_display":"5.20","price_state":"stated","total_value":14452.49,"total_display":"14,452.49","total_whole":"14,452","shares_owned_after":3070.0,"shares_owned_after_display":"3,070","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-09-01","filed_date":"2021-09-01","scope":"insider"},{"id":4458324,"accession":"0001104659-21-086385","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-21-086385","line_url":"/filing/0001104659-21-086385#line-1","is_derivative":false,"issuer_cik":"0001555851","issuer_name":"Adaptimmune Therapeutics PLC","issuer_ticker":"ADAP","issuer_name_source":null,"issuer_url":"/issuer/0001555851","owner_cik":"0001555851","owner_name":"Rawcliffe Adrian","owner_display_name":"Rawcliffe Adrian","owner_url":"/insider/0001555851","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"American Depositary Shares representing Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2794.0,"shares_display":"2,794","price_per_share":4.37,"price_display":"4.37","price_state":"stated","total_value":12209.78,"total_display":"12,209.78","total_whole":"12,210","shares_owned_after":3058.0,"shares_owned_after_display":"3,058","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-28","filed_date":"2021-06-28","scope":"insider"},{"id":4409691,"accession":"0001104659-21-005544","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-21-005544","line_url":"/filing/0001104659-21-005544#line-1","is_derivative":false,"issuer_cik":"0001555851","issuer_name":"Adaptimmune Therapeutics PLC","issuer_ticker":"ADAP","issuer_name_source":null,"issuer_url":"/issuer/0001555851","owner_cik":"0001555851","owner_name":"Rawcliffe Adrian","owner_display_name":"Rawcliffe Adrian","owner_url":"/insider/0001555851","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"American Depositary Shares representing Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9879.0,"shares_display":"9,879","price_per_share":5.6695,"price_display":"5.67","price_state":"stated","total_value":56008.9905,"total_display":"56,008.99","total_whole":"56,009","shares_owned_after":13529.0,"shares_owned_after_display":"13,529","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-01-19","filed_date":"2021-01-19","scope":"insider"},{"id":5535777,"accession":"0001104659-21-003590","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-21-003590","line_url":"/filing/0001104659-21-003590#line-1","is_derivative":false,"issuer_cik":"0001555851","issuer_name":"Adaptimmune Therapeutics PLC","issuer_ticker":"ADAP","issuer_name_source":null,"issuer_url":"/issuer/0001555851","owner_cik":"0001555851","owner_name":"Rawcliffe Adrian","owner_display_name":"Rawcliffe Adrian","owner_url":"/insider/0001555851","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"American Depositary Shares representing Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2707.0,"shares_display":"2,707","price_per_share":6.1522,"price_display":"6.15","price_state":"stated","total_value":16654.0054,"total_display":"16,654.01","total_whole":"16,654","shares_owned_after":3695.0,"shares_owned_after_display":"3,695","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-01-12","filed_date":"2021-01-12","scope":"insider"},{"id":5205699,"accession":"0001104659-21-001175","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-21-001175","line_url":"/filing/0001104659-21-001175#line-1","is_derivative":false,"issuer_cik":"0001555851","issuer_name":"Adaptimmune Therapeutics PLC","issuer_ticker":"ADAP","issuer_name_source":null,"issuer_url":"/issuer/0001555851","owner_cik":"0001555851","owner_name":"Rawcliffe Adrian","owner_display_name":"Rawcliffe Adrian","owner_url":"/insider/0001555851","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"American Depositary Shares representing Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4967.0,"shares_display":"4,967","price_per_share":5.3279,"price_display":"5.33","price_state":"stated","total_value":26463.6793,"total_display":"26,463.68","total_whole":"26,464","shares_owned_after":6737.0,"shares_owned_after_display":"6,737","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-01-04","filed_date":"2021-01-05","scope":"insider"},{"id":2922294,"accession":"0001104659-20-101976","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-20-101976","line_url":"/filing/0001104659-20-101976#line-1","is_derivative":false,"issuer_cik":"0001555851","issuer_name":"Adaptimmune Therapeutics PLC","issuer_ticker":"ADAP","issuer_name_source":null,"issuer_url":"/issuer/0001555851","owner_cik":"0001555851","owner_name":"Rawcliffe Adrian","owner_display_name":"Rawcliffe Adrian","owner_url":"/insider/0001555851","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"American Depositary Shares representing Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2776.0,"shares_display":"2,776","price_per_share":8.5149,"price_display":"8.51","price_state":"stated","total_value":23637.3624,"total_display":"23,637.36","total_whole":"23,637","shares_owned_after":3076.0,"shares_owned_after_display":"3,076","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-09-01","filed_date":"2020-09-02","scope":"insider"},{"id":2339942,"accession":"0001104659-20-090468","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-20-090468","line_url":"/filing/0001104659-20-090468#line-1","is_derivative":false,"issuer_cik":"0001555851","issuer_name":"Adaptimmune Therapeutics PLC","issuer_ticker":"ADAP","issuer_name_source":null,"issuer_url":"/issuer/0001555851","owner_cik":"0001555851","owner_name":"Rawcliffe Adrian","owner_display_name":"Rawcliffe Adrian","owner_url":"/insider/0001555851","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"American Depositary Shares representing Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2788.0,"shares_display":"2,788","price_per_share":9.25,"price_display":"9.25","price_state":"stated","total_value":25789.0,"total_display":"25,789.00","total_whole":"25,789","shares_owned_after":3064.0,"shares_owned_after_display":"3,064","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-08-03","filed_date":"2020-08-04","scope":"insider"},{"id":2516642,"accession":"0001104659-20-004420","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-20-004420","line_url":"/filing/0001104659-20-004420#line-1","is_derivative":false,"issuer_cik":"0001555851","issuer_name":"Adaptimmune Therapeutics PLC","issuer_ticker":"ADAP","issuer_name_source":null,"issuer_url":"/issuer/0001555851","owner_cik":"0001555851","owner_name":"Rawcliffe Adrian","owner_display_name":"Rawcliffe Adrian","owner_url":"/insider/0001555851","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"American Depositary Shares representing Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3236.0,"shares_display":"3,236","price_per_share":5.1347,"price_display":"5.13","price_state":"stated","total_value":16615.8892,"total_display":"16,615.89","total_whole":"16,616","shares_owned_after":3166.0,"shares_owned_after_display":"3,166","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-01-14","filed_date":"2020-01-15","scope":"insider"},{"id":2862089,"accession":"0001104659-20-002080","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-20-002080","line_url":"/filing/0001104659-20-002080#line-1","is_derivative":false,"issuer_cik":"0001555851","issuer_name":"Adaptimmune Therapeutics PLC","issuer_ticker":"ADAP","issuer_name_source":null,"issuer_url":"/issuer/0001555851","owner_cik":"0001555851","owner_name":"Rawcliffe Adrian","owner_display_name":"Rawcliffe Adrian","owner_url":"/insider/0001555851","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"American Depositary Shares representing Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5900.0,"shares_display":"5,900","price_per_share":1.2,"price_display":"1.20","price_state":"stated","total_value":7080.0,"total_display":"7,080.00","total_whole":"7,080","shares_owned_after":5804.0,"shares_owned_after_display":"5,804","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-01-06","filed_date":"2020-01-07","scope":"insider"},{"id":7912519,"accession":"0001104659-19-002163","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-19-002163","line_url":"/filing/0001104659-19-002163#line-1","is_derivative":false,"issuer_cik":"0001555851","issuer_name":"Adaptimmune Therapeutics PLC","issuer_ticker":"ADAP","issuer_name_source":null,"issuer_url":"/issuer/0001555851","owner_cik":"0001555851","owner_name":"Rawcliffe Adrian","owner_display_name":"Rawcliffe Adrian","owner_url":"/insider/0001555851","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"American Depositary Shares representing Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3084.0,"shares_display":"3,084","price_per_share":5.3694,"price_display":"5.37","price_state":"stated","total_value":16559.2296,"total_display":"16,559.23","total_whole":"16,559","shares_owned_after":3318.0,"shares_owned_after_display":"3,318","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-01-14","filed_date":"2019-01-16","scope":"insider"},{"id":6517090,"accession":"0001104659-18-019665","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-18-019665","line_url":"/filing/0001104659-18-019665#line-1","is_derivative":false,"issuer_cik":"0001555851","issuer_name":"Adaptimmune Therapeutics PLC","issuer_ticker":"ADAP","issuer_name_source":null,"issuer_url":"/issuer/0001555851","owner_cik":"0001555851","owner_name":"Rawcliffe Adrian","owner_display_name":"Rawcliffe Adrian","owner_url":"/insider/0001555851","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":600000.0,"shares_display":"600,000","price_per_share":1.71,"price_display":"1.71","price_state":"stated","total_value":1026000.0,"total_display":"1,026,000.00","total_whole":"1,026,000","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-03-20","filed_date":"2018-03-22","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":34,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":34,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":34},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001631574","name":"Wave Life Sciences, Inc.","url":"/issuer/0001631574","role":"Director","n_filings":3,"first_seen":"2025-11-14","last_seen":"2026-08-13"},{"type":"issuer","type_label":"ISSUER","cik":"0001621227","name":"Adaptimmune Therapeutics PLC","url":"/issuer/0001621227","role":"Director, Officer (Chief Executive Officer)","n_filings":25,"first_seen":"2018-03-22","last_seen":"2025-01-17"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001555851","retrieved_at":"2026-08-27T12:08:28+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-26","last_ingest":"2026-08-27T05:24:39.644631+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}